Haemonetics
NYSE:HAE Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
WA
Consensus Narrative from 10 Analysts
Shift To High-Margin Interventional Technologies Will Strengthen Future Prospects
Key Takeaways Strategic divestitures and focus on high-margin segments expected to enhance profitability and drive revenue and margin growth. New agreements and innovations in Blood Management Technologies position Haemonetics for significant market share increases and global technology adoption.
View narrativeUS$96.80
FV
32.3% undervalued intrinsic discount5.55%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
5 days ago author updated this narrative